Drug Design, Development and Therapy (May 2016)
Reducing the trigger dose of recombinant hCG in high-responder patients attending an assisted reproductive technology program: an observational study
Abstract
Gian Mario Tiboni, Enrica Concetta Colangelo, Adalisa Ponzano Department of Medicine and Aging Sciences, University “G d’Annunzio” of Chieti-Pescara, Chieti, Italy Abstract: Decreasing the dose of human chorionic gonadotropin (hCG) used to trigger final oocyte maturation in assisted reproductive technology programs is regarded as a useful intervention in the prevention of ovarian hyperstimulation syndrome, but the minimal effective dose has not been yet identified. In this study, the capacity of a reduced dose of recombinant hCG (r-hCG) to provide adequate oocyte maturation was tested for the first time. Thirty-five high-responder patients received a dose of 125 µg (half of the standard dose) of r-hCG for triggering final oocyte maturation. The number of oocytes retrieved per patient and the proportion of mature oocytes were evaluated. As a result, a mean number of 14 oocytes were retrieved, of which 85% were found to be mature (MII). There was only one patient developing a moderate form of ovarian hyperstimulation syndrome and not requiring hospitalization. It is suggested that r-hCG at 125 µg can be effective in triggering final oocyte maturation in high-responder patients. Additional properly powered and controlled studies are needed to support this contention. Keywords: recombinant hCG, low dose, triggering oocyte maturation, OHSS
